Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/102125
Title: Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype -ACOSOG Z1031
Author: Ellis, Matthew J.
Suman, Vera J.
Hoog, Jeremy
Lin, Li
Snider, Jacqueline
Prat Aparicio, Aleix
Parker, Joel S.
Luo, Jingqin
DeSchryver, Katherine
Allred, D.Craig
Esserman, Laura J.
Unzeitig, Gary W.
Margenthaler, Julie
Babiera, Gildy V.
Marcom, P. Kelly
Guenther, Joseph M.
Watson, Mark A.
Leitch, Marylin
Hunt, Kelly
Olson, John A.
Keywords: Càncer de mama
Receptors d'hormones
Estrògens
Menopausa
Assaigs clínics de medicaments
Breast cancer
Hormone receptors
Estrogen
Menopause
Drug testing
Issue Date: 10-Jun-2011
Publisher: American Society of Clinical Oncology
Abstract: PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations. PATIENTS AND METHODS: Three hundred seventy-seven postmenopausal women with clinical stage II to III ER-positive (Allred score 6-8) breast cancer were randomly assigned to receive neoadjuvant exemestane, letrozole, or anastrozole. The primary end point was clinical response. Secondary end points included BCS, Ki67 proliferation marker changes, the Preoperative Endocrine Prognostic Index (PEPI), and PAM50-based intrinsic subtype analysis. RESULTS: On the basis of clinical response rates, letrozole and anastrozole were selected for further investigation; however, no other differences in surgical outcome, PEPI score, or Ki67 suppression were detected. The BCS rate for mastectomy-only patients at presentation was 51%. PAM50 analysis identified AI-unresponsive nonluminal subtypes (human epidermal growth factor receptor 2 enriched or basal-like) in 3.3% of patients. Clinical response and surgical outcomes were similar in luminal A (LumA) versus luminal B tumors; however, a PEPI of 0 (best prognostic group) was highest in the LumA subset (27.1% v 10.7%; P = .004). CONCLUSION: Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1200/JCO.2010.31.6950
It is part of: Journal of Clinical Oncology, 2011, vol. 29, num. 17, p. 2342-2349
Related resource: http://dx.doi.org/10.1200/JCO.2010.31.6950
URI: http://hdl.handle.net/2445/102125
ISSN: 0732-183X
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
660925.pdf151.46 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.